Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
Baudin E, Goichot B, Berruti A, Hadoux J, Moalla S, Laboureau S, Nölting S, de la Fouchardière C, Kienitz T, Deutschbein T, Zovato S, Amar L, Haissaguerre M, Timmers H, Niccoli P, Faggiano A, Angokai M, Lamartina L, Luca F, Cosentini D, Hahner S, Beuschlein F, Attard M, Texier M, Fassnacht M; ENDOCAN-COMETE; ENSAT Networks. Baudin E, et al. Among authors: attard m. Lancet. 2024 Mar 16;403(10431):1061-1070. doi: 10.1016/S0140-6736(23)02554-0. Epub 2024 Feb 22. Lancet. 2024. PMID: 38402886 Clinical Trial.
Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
Hadoux J, Al Ghuzlan A, Lamartina L, Bani MA, Moog S, Attard M, Scoazec JY, Hartl D, Aldea M, Friboulet L, Jules-Clement G, Italiano A, Besse B, Lacroix L, Baudin E. Hadoux J, et al. Among authors: attard m. JCO Precis Oncol. 2023 Sep;7:e2300053. doi: 10.1200/PO.23.00053. JCO Precis Oncol. 2023. PMID: 38127829
When a fungal infection is worse than a leukemia diagnosis.
Attard JA, Attard M. Attard JA, et al. Among authors: attard m. Transpl Infect Dis. 2023 Nov;25 Suppl 1:e14189. doi: 10.1111/tid.14189. Epub 2023 Nov 27. Transpl Infect Dis. 2023. PMID: 38010719 No abstract available.
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer.
Leboulleux S, Benisvy D, Taieb D, Attard M, Bournaud C, Terroir-Cassou-Mounat M, Lacroix L, Anizan N, Schiazza A, Garcia ME, Ghuzlan AA, Lamartina L, Schlumberger M, Godbert Y, Borget I. Leboulleux S, et al. Among authors: attard m. Thyroid. 2023 Sep;33(9):1124-1129. doi: 10.1089/thy.2023.0240. Epub 2023 Jul 26. Thyroid. 2023. PMID: 37350119 Clinical Trial. No abstract available.
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, Benisvy D, Taïeb D, Bardet S, Terroir-Cassou-Mounat M, Anizan N, Bouvier-Morel E, Lamartina L, Lion G, Betrian S, Sajous C, Schiazza A, Garcia ME, Ciappuccini R, Schlumberger M, Al Ghuzlan A, Godbert Y, Borget I. Leboulleux S, et al. Among authors: attard m. Clin Cancer Res. 2023 Jul 5;29(13):2401-2409. doi: 10.1158/1078-0432.CCR-23-0046. Clin Cancer Res. 2023. PMID: 37074727 Clinical Trial.
103 results